A pharmacoeconomic model populated with local parameters is needed for vaccine decision-making. The aim of the study was to provide a CEA of PCV7 in Taiwan and explore the impact of herd effect and indirect cost on the findings of CEA. Methods: A decision analytic model was populated with local epidemiological and economic data to simulate the expected clinical and economic outcomes from a hypothetical vaccinated birth cohort of 191,310 infants compared to no vaccination over a 10-year time horizon. To explore the impact of herd effect, results were presented with and without herd effect. Moreover, the study was conducted from both payer and societal perspectives to examine the impact of indirect cost. One-way sensitivity analyses were performed to evaluate model robustness. The cost-effectiveness of a reduced three-dose schedule was also estimated. 
Background/Purpose: Pneumococcal diseases caused by Streptococcus pneumoniae can lead to significant morbidity and mortality in young infants and the elderly. The seven-valent pneumococcal conjugate vaccine (PCV7) has been available on the private market in Taiwan since October 2005. To date, there has not been any cost-effectiveness analysis (CEA) of PCV7 in Taiwan. A pharmacoeconomic model populated with local parameters is needed for vaccine decision-making. The aim of the study was to provide a CEA of PCV7 in Taiwan and explore the impact of herd effect and indirect cost on the findings of CEA. Methods: A decision analytic model was populated with local epidemiological and economic data to simulate the expected clinical and economic outcomes from a hypothetical vaccinated birth cohort of 191,310 infants compared to no vaccination over a 10-year time horizon. To explore the impact of herd effect, results were presented with and without herd effect. Moreover, the study was conducted from both payer and societal perspectives to examine the impact of indirect cost. One-way sensitivity analyses were performed to evaluate model robustness. The cost-effectiveness of a reduced three-dose schedule was also estimated.
Results: PCV7 vaccination could prevent 1281 cases of invasive pneumococcal diseases, 178,145 cases of all-cause hospitalized pneumonia, 69,962 cases of all-cause acute otitis
Introduction
Streptococcus pneumoniae is a bacterial pathogen responsible for significant morbidity and mortality worldwide. Infection with S pneumoniae may be invasive (meningitis and bacteremia, collectively reported as IPD) or noninvasive (non-bacteremic pneumonia and otitis media) depending on the site of infection. In Taiwan, pneumococcal disease is a major healthcare burden, particularly in young children and the elderly. 1, 2 Since October 2007, IPD has been a notifiable disease to the Centers for Disease Control (CDC) in Taiwan.
While penicillin remains the drug of choice for patients with pneumococcal disease, the growing incidence of penicillin-resistant S pneumoniae is a concern worldwide and has complicated disease management. 3 Furthermore, studies have shown that patients with resistant pneumococcal infections often require longer hospital stays and greater resource utilization to manage their condition, highlighting the potential economic consequences of increasing resistance rates of this bacterium. 4, 5 A study in Taiwan indicated that 80.7% of S pneumoniae isolates obtained from children under 14 years of age were found to be resistant to penicillin (intermediate resistance 16 .3% and resistant 67.4%). 6 Such rates indicate that despite the implementation of stringent antibiotic prescribing protocols, Taiwan has one of the highest rates of antibiotic resistant S pneumoniae globally.
The pneumococcal conjugate vaccine has been considered a priority for inclusion in national childhood immunization programs by the World Health Organization (WHO) since 2007, with an aim to reduce the burden of pneumococcal diseases worldwide. 7 Although there are around 90 known serotypes of S pneumoniae, most pneumococcal diseases are only caused by a few serotypes. 8 Providing immunologic protection against these serotypes could protect against the majority of S pneumoniae-related infections. In view of this, vaccines to provide protection against some of the most common serotypes have been developed, including the seven-valent pneumococcal conjugate vaccine (PCV7), a heptavalent conjugate vaccine that contains saccharides of the capsular antigen of S pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F individually conjugated to a diphtheria CRM 197 protein. The effects of this vaccine have been studied in Taiwan, with results indicating that it is considered to be efficacious and safe in Taiwanese children. 9 However, judging from the already crowded vaccination schedules in the National Immunization Program (NIP), decision-making in regards to introducing new vaccines into the NIP has been gradually emphasized and will require an economic evaluation to achieve this goal. Therefore, the role of CEA in health economics has gained its spotlight in decision-making of newly developed vaccines in various countries. In addition to the hurdles of licensing a new vaccine, quality control, manufacturing, and verifying its efficacy in clinical trial, CEA of vaccine has been added as another hurdle which provides important impact for its reimbursement in government vaccination policy. In view of this, our CEA of PCV7 in Taiwan will provide an important avenue to achieve this goal.
In terms of the benefit of a national vaccination program, in countries where PCV7 has been introduced into the routine vaccination schedule, rates of pneumococcal disease have decreased in not only vaccinated infants, but also in the unvaccinated adult populations.
10e13 This effect, referred to as "herd protection," occurs when vaccination reduces the spread of a pathogen from infants to unvaccinated children and adults and in turn reduces their risk of contracting a disease. It has been shown by the US Centers for Disease Control and Prevention Active Bacterial Core Surveillance that the elderly above 65 years of age can benefit indirectly from the universal infant PCV7 vaccination through the well-known herd effect as a kind of indirect protection of unvaccinated susceptible individuals with lower risk to be infected with the disease.
14 A longterm observational study in the US indicated that the childhood PCV7 vaccination was estimated to prevent around 38,000 cases of IPD among a vaccinated cohort for the first 5 years after vaccination with US$112,000 per life year saved. If further considering herd effect, the vaccination prevented additional 109,000 cases of IPD and led to smaller incremental cost-effectiveness ratio (ICER) of US$7500 per life year saved. Therefore, the impact of herd effect on economic evaluation of a vaccine is huge.
The Advisory Committee on Immunization Practices (ACIP) in Taiwan was established under the CDC in 1986. The mission of the ACIP is to provide important advice such as general criteria for a vaccine to be included for the NIP according to disease burden and public health nature of the infection and vaccine procurement funding and to convey timely advice on specific vaccine in case of unexpected and sudden disease outbreak. Nevertheless, with limited medical resources, the growing pressure of healthcare expenditure has made CEA of vaccine a vital issue within the operational framework of the ACIP. The independent health economic assessment from using pharmaecoeconomic model will provide decision makers such as the ACIP with more scientific evaluation of a particular national vaccination program in order to allocate medical resources in a more efficient manner. In view of this, an economic evaluation of the cost-effectiveness of universal infant vaccination with PCV7 will be useful to guide reimbursement decisions about including the vaccine in the NIP in Taiwan. Although cost-effectiveness analyses of PCV7 have been undertaken in other countries, their findings cannot be generalized in the context of Taiwan due to differences in disease epidemiology, serotype prevalence, medical costs, and clinical practice, which are major inputs for a vaccine pharmacoeconomic model. Therefore, the objective of this study was to populate the pharmacoeconomic model with local parameters collected from various sources such as large database, randomized clinical trials, observational studies, case-control studies, and local experts' opinions in order to acquire country-specific outcomes. The second objective of the study was to provide an economic evaluation of universal infant PCV7 vaccination in Taiwan and explore the impact of herd effect and indirect cost on the findings of costeffectiveness results.
Methods

Decision analytic model
To estimate the long-term outcomes associated with vaccination, an age-stratified decision analytic model was adapted to simulate the expected health outcomes resulting from universal PCV7 vaccination of a birth cohort of 191,310 Taiwanese infants compared with no vaccination over a 10-year time horizon. 15 The decision tree analysis is a kind of scenario analysis. In the branch with the absence of vaccination, we assume a hypothetical cohort to represent newly born infants free of pneumococcal diseases in the year of 2009 but will later be likely infected with the diseases. In another branch with vaccination, another identical hypothetical cohort of newly born infants is assumed to be infected with pneumococcal diseases with lower risk. Vaccine efficacy rates against four types of pneumococcal disease, including pneumonoccal meningitis, pneumococcal bacteremia, all-cause hospitalized pneumonia, and all-cause acute otitis media (AOM), were included in the model to calculate the lower risk of disease contraction.
Demographic data
Population data stratified by age groups, non-S. pneumoniae-related mortality rates, and the life years lost in each age group due to S pneumoniae-related deaths were derived from Taiwan government sources. 16 Details are presented in Table 1 .
Epidemiological data
The epidemiological parameters used in this study and their respective sources are summarized in Table 1 . Average age-specific incidence rates for IPD, hospitalized all-cause pneumonia, and all-cause AOM were estimated using data from the National Health Insurance Research Database (NHIRD; 2002e2004) to represent the pre-vaccination disease trends before PCV7 introduction into the private market in Taiwan in 2005. As there is no microbiological information from NHIRD, we used defined ICD9 codes in NHIRD to capture disease cases: 320.1 for pneumococcal meningitis; 038.2, 038.9, and 790.7 for pneumococcal bacteremia excluding 482, 486, and 510.9; 481e486 and 4870 for allcause pneumonia; 381, 381.0, 382, 382.0, 382.4, 382.9, and 384.0 for AOM. Mortality due to microbiologically confirmed IPD was estimated using the CDC database. 17 Mortality due to all-cause hospitalized pneumonia was obtained from the NHIRD using the NHIRD death code before hospital discharge.
Cost data
The average direct medical costs of pneumococcal diseases were determined from the payer perspective using the NHIRD (2002e2004), to represent the costs borne by the Taiwanese healthcare system. These costs cover the direct medical resources consumed in the treatment of pneumococcal disease, including hospitalization, healthcare professional consultation fees, intensive care admissions, medications, and diagnostic tests. Using the same set of ICD9 codes, the average annual direct cost for a particular pneumococcal disease was estimated by dividing the total direct cost of a pneumococcal disease by the total number of episodes for those 3 years (2002e2004).
An analysis which included costs determined from a societal perspective was also conducted, which included both direct medical costs, and indirect costs such as the cost of productivity lost by a patient due to either nonfatal pneumococcal diseases or premature death, and caregiver time. Indirect costs were estimated using the human capital approach. 18 Using this approach, it was assumed that a half-day of work time was lost for each outpatient visit and a full-day of work time was lost for each day of hospitalization. For children under 18 years of age with a pneumococcal infection, one parent was assumed to miss work for the child's outpatient or inpatient visits. Full-time employment was assumed for people 18e65 years of age. The cost of work loss for parents can then be estimated using wage information from the website of Directorate General of Budget, Accounting and Statistics, Executive Yuan in Taiwan. 19 If an adult is infected with the disease, then his or her length of stay in hospital multiplied by the daily wage obtained from the same government website can be used to estimate the cost of work loss of each patient. The expected cost of productivity lost due to pneumococcal death was estimated by multiplying the life expectancy of a patient (derived from the median age of death for each age group), with the average annual earnings for the corresponding age group. 19 Transportation cost is assumed to be NT$100 for both children and adults. The breakdown of the individual costs included in the model and their data sources are presented in Table 2 .
Vaccine efficacy data
Vaccine efficacy against IPD was derived from the Northern California Kaiser Permanente pivotal trial. 20 The average efficacy rate of PCV7 against IPD was calculated by multiplying the efficacy of PCV7 seen in the Intent-to-Treat group in the Northern California Kaiser Permanente trial d i.e., 94%, with the expected coverage of PCV7 in Taiwan against the seven vaccine serotypes. 21 The efficacy of PCV7 against all-cause hospitalized pneumonia was estimated to be 25.5% in line with a study which assessed vaccine efficacy against pneumonia confirmed using WHO-standardized methodology. 22 The efficacy of PCV7 against AOM was estimated to be 7%, in line with the Finnish Otitis Media vaccine trial. 23 Vaccine-induced immunity was assumed to wane by 1% per year for the first 5 years following initial vaccination and by 3% annually for years 6e10. 14 
Herd effect data
Age-specific estimates of the anticipated herd effect of PCV7 on unvaccinated adult populations were considered by calculating the expected reduction in adult cases of IPD in line with the published rates from the US experience. 11 The midpoint estimates for the herd effect in each age group were used in the primary analysis: 32% (range 23e41%) for adults aged 20e39 years, 8% (range 1e20%) for adults aged 40e64 years, and 18% (range 11e31%) for adults aged !65 years. A reduction in the number of cases of hospital-treated pneumonia in adults was also assumed to occur from the herd effect, with rates appropriated from published literature: 26% (range 4e43%) for adults aged 20e39 years, 19% (range -3% to 35%) for adults aged 40e64 years, and 15% (range -2% to 30%) for adults aged !65 years. 24 Data on the possible herd effect of PCV7 vaccination on adult cases of AOM were not evident, and hence herd effect on adult AOM was not considered in the study.
Cost of PCV7 vaccination program
The cost of introducing a universal vaccination program included both PCV7 acquisition and administration costs. The acquisition cost of PCV7 was assumed to be NT$2500 (US$78.5) per dose, as the current price of the vaccine in 
Vaccination administration
A four-dose vaccination schedule was assumed for the birth cohort (i.e., infants less than 6 months of age) in the basecase analysis, as a primary series of three doses at 2, 4, and 6 months of age, and a booster (fourth) dose administered in the second year of life at 12e15 months of age. A reduced three-dose schedule was also analyzed in scenario secondary analysis. A vaccination coverage rate of 90% was assumed for all newly born infants in line with the US Department of Health's goal of achieving 90% coverage rates for all routine childhood vaccinations by 2010. 26 
Cost-effectiveness analysis
The cost-effectiveness of a universal PCV7 vaccination program was calculated in terms of ICER as shown below:
where DCZC vac À C none Z incremental cost (vaccination vs. no vaccination); DEZE vac À E none Z incremental effectiveness (vaccination vs. no vaccination).
If effectiveness refers to life year, then ICER can be interpreted as incremental cost per life-year gained (LYG).
Life-years were used to measure deaths avoided, where each death prevented at a certain age group was equated to a certain number of life years, depending on the age at which the death was expected to occur and the life expectancy of the individual. For example, each childhood death avoided in Taiwan was equal to the life expectancy at birth (approximately 75 years) minus the child's age at the time of death. A discount rate of 3% was applied to both costs and benefits in the base-case analysis.
As yet, there is no explicit threshold value for cost per life-year gained in Taiwan. However, the World Health Organization CHOICE (CHOosing Interventions that are CostEffective) group has developed guidelines on generalized cost-effectiveness analyses for public health interventions and indicates that interventions which cost less than three times the average per capita income per outcome unit are cost effective. With respect to this threshold, universal PCV7 vaccination would be considered cost-effective in Taiwan if the incremental cost per life-year gained is below NT$2,704,410 (using the 2009 GDP per capita of NT$901,470) either in the payer or the societal perspective.
Sensitivity analysis
A series of one-way sensitivity analyses were performed to evaluate the sensitivity of the findings to plausible variation in specific data inputs. Parameters were varied by AE50% from the base-case estimates. The estimates of the herd effect were varied between the lower and upper bounds surrounding their 95% confidence intervals. The results are presented in a tornado diagram (Fig. 1) . Since the objective of this study was to consider the cost-effectiveness of PCV7 vaccination, with and without a herd effect, a conventional a Due to the low incidence of AOM in older children and adults, we assume that persons aged !10 years are not at risk of AOM.
CEA was considered the most valid approach, and a probabilistic sensitivity analysis (PSA) was therefore not conducted to avoid introducing more uncertainty into the model. 27 
Results
Clinical outcomes
The clinical impact of PCV7 vaccination with respect to the number of cases of pneumococcal disease and deaths avoided in both the birth cohort and the unvaccinated age-stratified adult populations are presented in Table 3 . In the birth cohort alone, universal PCV7 vaccination was estimated to prevent 50 cases of IPD (7 cases of meningitis and 43 cases of bacteremia), 13,782 cases of all-cause hospitalized pneumonia, 69,962 cases of AOM, and 41 deaths, equivalent to a gain of 1269 life-years. With the inclusion of the herd effect, a total of 14,926 life-years were gained through the prevention of an additional 364 cases of meningitis (192 cases in the 20e34 age group; 48 cases in the 35e64 age group; 124 cases in the 65þ age group), 867 cases of bacteremia (314 cases in the 20e34 age group; 149 cases in the 35e64 age group; 405 cases in the 65þ age group), 164,363 cases of all-cause hospitalized pneumonia (37,109 cases in the 20e34 age group; 27,136 cases in the 35e64 age group; 100,118 cases in the 65þ age group), and 940 deaths (136 deaths in the 20e34 age group; 52 deaths in the 35e64 age group; 752 deaths in the 65þ age group) in the unvaccinated adult population. Among the three age groups, herd effect is most influential in the 65þ age group, followed by the 20e34 age group, and the 35e64 age group. This is reasonable in that the 65þ age group is another high-risk group for pneumococcal infection. a Due to the low incidence of AOM in older children and adults, we assume that persons aged !10 years are not at risk of AOM.
Economic outcomes
A summary of treatment costs saved as a result of PCV7 vaccination in terms of direct cost and indirect costs is presented in Table 4 , where results of direct and herd effect are displayed separately. Over a 10-year time horizon, the implementation of a universal infant PCV7 vaccination program requires an annual cost of NT$1,950.5 million (US$61.26 million). Considering direct medical cost, NT$346 million (US$10.87 million) can be saved due to direct effect, and an additional NT$5,663 million (US$177.87 million) can be saved due to herd effect (NT$10.78 million in the 20e34 age group; NT$19.08 million in the 35e64 age group; NT$148.02 million in the 65þ age group), resulting in a total saving of NT$6,010 million (US$188.75 million) in all age groups. In terms of indirect cost, NT$638 million (US$20.04 million) can be saved due to direct effect and an additional NT$2,819 million (US$612.61 million) can be saved due to herd effect (NT$270 million in the 20e34 age group; NT$269 million in the 35e64 age group; NT$2,280 million in the 65þ age group), leading to a total saving of NT$3,457 million (US$612.61 million) in all age groups.
Cost-effectiveness results
The base-case cost-effectiveness outcomes with and without herd effect are shown in Table 5 . Without the inclusion of herd effect, assuming a four-dose vaccination schedule, PCV7 vaccination will have an ICER of NT$15,093,230 (US$474,034) in payer perspective and NT$14,590,626 (US$458,248) in societal perspective. Reducing the total vaccination cost by 25% (i.e., a threedose vaccination schedule), the vaccination will lead to a lower ICER of NT$11,251,735 (US$353,384) in payer perspective and NT$10,434,018 (US$327,702) in societal perspective. Accounting for herd effect, and assuming a four-dose vaccination schedule, universal vaccination with PCV7 is expected to have an incremental cost of NT$1,183,028 (US$37,155) per LYG from the payer perspective and NT$619,862 (US$19,468) per LYG from the societal perspective. When a three-dose vaccination schedule is assumed and the herd effect is taken into account, universal vaccination with PCV7 has an incremental cost of NT$422,671 (US$13,275) per LYG from the payer perspective and NT$184,511 (US$5795) per LYG from the societal perspective.
Sensitivity analyses
The results of the various one-way sensitivity analyses are presented in a tornado diagram shown in Fig. 1 . The ICER was most sensitive to vaccine price, herd effect on pneumonia, mortality rate of pneumonia, and indirect cost of pneumonia.
Discussion
This study is the first pharmacoeconomic evaluation conducted on the predicted impact of infant vaccination with PCV7 completed in Taiwan and serves as a useful example, both in a local context and for other decision-makers in the Asia Pacific region, on the potential benefits of introducing this vaccine into the national childhood immunization schedule. In this study, we populated a decision analytic model with the most recent local epidemiological and cost data available from the NHIRD, Taiwan CDC database, and published literature to estimate country-specific clinical and economic benefits, as well as the cost-effectiveness, of universal PCV7 vaccination in Taiwan. The results of our base-case analysis suggest that including a four-dose PCV7 vaccination program in the NIP in Taiwan will be a costeffective intervention in a payer perspective if herd effect is taken into account according to WHO-recommended threshold. When the indirect costs are considered in the societal perspective, universal PCV7 vaccination program is even more cost-effective, producing a more favorable ICER. The three-dose vaccination program in both perspectives will be more cost-effective compared to four-dose counterparts. The exclusion of herd effect from the analysis indicates that the vaccination program is not cost-effective in both perspectives. Results from the one-way sensitivity analyses showed that the key factor that had the greatest impact on ICER was vaccine price. Herd effect on pneumonia, mortality rate of pneumonia, and indirect cost of pneumonia also had considerable impact on ICER.
In several countries where PCV7 has been included in the NIP, observational studies have indicated that the vaccination of specific populations not only provides vaccinated individuals with protection against pneumococcal disease, but also reduces the risk of unvaccinated individuals from developing both IPD and non-IPD. 10 In the US, a postvaccination observational study estimated that PCV7 vaccination has prevented more than twice as many cases of pneumococcal disease through the herd effect than through its direct effect of protecting vaccinated children. 20 In our study, we incorporated the estimates of the herd effect seen in the US, in the absence of local data. Our model attempted to mimic the benefit of herd effect by assuming that the risk pneumococcal diseases in Taiwan would decrease by the same proportion as was observed in the US. Herd effect and indirect cost have been shown to have enormous impact on the cost-effectiveness results in this study. In terms of those two influential factors, the findings of our study are consistent with the CEA of PCV7 conducted in other countries which showed that the clinical benefit of the herd effect has been a major driver of costeffectiveness of the nationwide PCV7 vaccination program. Several previous studies of PCV7 from Hong Kong, Germany, the US, and the UK have also shown that the inclusion of herd effect had led to a significant and consistent improvement in cost-effectiveness results in favor of universal vaccination with PCV7. In Hong Kong, PCV7 vaccination for 10 years will produce an ICER of US$6460 and US$5929 in both payer and societal perspectives, respectively, when herd effect is considered. The exclusion of herd effect will increase the ICER to US$260,523 and US$246,353 in both payer and societal perspectives, respectively. In Germany, it was estimated that the ICER of only vaccinating children at high risk was US$53,603 and of vaccinating the entire birth cohort was US$141,240 gained without considering herd effect. If herd effect is considered, the ICER was greatly lowered to US$230. 28 A study in the US yielded an ICER of US$35,043 without herd effect and US$11,089 if herd effect is considered. 29 Another study in England and Wales has also indicated a lower ICER from US$158,700 to US$42,181, when herd effect was considered. 30 A study in the UK suggested an ICER which decreased from US$57,968 to US$21,863 when accounting for herd effect. 15 The NHIRD dataset contains data on ambulatory care, inpatient care, dental services, and prescription drugs, which have been collected for 96e99% of the population since 1995. Given the high coverage rate of this database, it was assumed that the data in our analyses were sufficiently representative of the true clinical and economic consequences of pneumococcal disease on a national level in Taiwan. In addition, microbiologically confirmed cases of IPD obtained from the Taiwan CDC database, which were used to estimate age-specific IPD mortality rates, were also considered reliable.
As in any CEA, the overestimation or underestimation of pharmacoeconomic results is driven, in part, by limitations in the study design. In this study, we did not take account for the fact that PCV7 vaccination might increase carriage of non-vaccine serotypes. If an increase in nonvaccine serotypes occurs, this may increase the overall disease burden, in which case the observed effect of PCV7 against the disease burden may be reduced. This, in turn, may worsen the cost-effectiveness of PCV7 (i.e., lead to an increase in ICER). Another omission from our study, which may lead to an overestimation of the effect of vaccination, was the cost of potential adverse effects of the PCV7 vaccine. In addition, costs associated with running nationwide disease surveillance to monitor the emergence of non-vaccine serotypes following vaccination were also not considered due to the difficulty in estimating these costs. Lastly, the benefit of vaccination was quantified in terms of life years gained (without utility weightings for each clinical presentation of pneumococcal disease or their complications) instead of considering the impact on quality of life. This outcome measure was chosen in the absence of robust quality of life data for infants in Taiwan.
On the other hand, there were several factors not considered in the model which may have led to the underestimation of some of the pharmacoeconomic results. First, the potential effect of vaccination on other clinical presentations of pneumococcal disease such as sinusitis and septic arthritis was not included in the analysis. In addition, the assumed incidence of pediatric pneumonia was considered to be conservative, as only hospitalized cases (i.e., severe cases) were included. It is likely that these rates may underestimate the true burden of pneumonia seen in the community. Second, the herd effect in older children aged 10e19 years was not considered in this analysis, as it was assumed that their disease burden would be relatively low. Vaccination with PCV7 could also provide protection against these aforementioned infections and their inclusion in CEAs would likely further improve the cost-effectiveness of the vaccine. Thirdly, the potential cost savings from preventing complications of meningitis, such as deafness, brain damage, focal neurological deficit, and chronic seizures, were also not included in the present analysis primarily due to a lack of local incidence and cost estimates for these conditions. Table 5 Cost-effectiveness outcomes: incremental cost-effectiveness ratio (ICER) in both payer and societal perspectives and for direct and herd effect, respectively. Current international standards for conducting economic evaluations recommend the use of multivariate PSA to express parameter uncertainty. 31 However, because the objective of our study was to consider the costeffectiveness of PCV7 vaccination, with and without herd effect and indirect cost, a conventional CEA is considered appropriate, and the PSA is therefore not conducted to avoid introducing more uncertainty into the model.
In line with many studies of PCV7 vaccination which have been conducted worldwide, 7 the assumed herd effect of PCV7 was the largest driver of uncertainty around the costeffectiveness results. The herd effect of vaccination depends predominantly on population factors, such as social contact structure and vaccination coverage rates, which vary from country to country, and even within the same country from year to year. Therefore, it is possible that the herd effect observed in the US and used in our study may not accurately reflect the local herd effects which would occur following routine PCV7 vaccination of infants in Taiwan. Future research will focus on developing a transmission dynamic model to take account of the effects of PCV7 vaccination on a local level and thereby acquire improved cost-effectiveness results of the impact of universal pneumococcal vaccination in Taiwan. Despite the model choice, it is however suggested that any further pharmacoeconomic model should always include herd effect due to its huge impact when performing a CEA in infectious disease research.
Universal infant PCV7 vaccination in Taiwan is expected to lead to a substantial reduction in the incidence of pneumococcal-related clinical presentations in both children and adults. The cost savings resulting from both the direct and herd effect of vaccination imply that PCV7 is a cost-effective intervention with respect to the WHO's threshold for cost-effectiveness and a worthwhile investment to protect the Taiwan population against pneumococcal disease.
